Q2 2023 Scandion Oncology A/S Earnings Call Transcript
Welcome to Scandion Oncology Q2-Report 2023. (Operator Instructions) Now, I will hand the conference over to CEO, Francois Martelet; and CFO, Johnny Stilou. Please go ahead.
/-
Thank you very much, and good morning to everyone, and welcome to our Q2-2023 interim-report investor call. You heard my name Francois Martelet, I'm the CEO of Scandion Oncology. With me today is our Chief Financial Officer, Johnny Stilou. Johnny and I will be updating you on the development and financial results for the second quarter of 2023, as well as recent events post quarter.
We had indeed a good second quarter in which we maintained our strong operational momentum and made several efforts to derisk our development pipeline, and therefore, as such, our company. And I will speak about that in more details shortly.
Following our presentation, Johnny and I are delighted to answer any question you may have. Please be informed that to best address your questions, we ask you to state this
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |